J.P. Marvel Investment Advisors LLC decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.9% during the third quarter, Holdings Channel reports. The fund owned 81,738 shares of the company’s stock after selling 770 shares during the period. AbbVie comprises approximately 1.8% of J.P. Marvel Investment Advisors LLC’s holdings, making the stock its 23rd largest position. J.P. Marvel Investment Advisors LLC’s holdings in AbbVie were worth $5,155,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. Kempen Capital Management N.V. purchased a new position in AbbVie during the third quarter worth $19,889,000. Alps Advisors Inc. boosted its position in AbbVie by 14.6% in the second quarter. Alps Advisors Inc. now owns 443,246 shares of the company’s stock worth $27,441,000 after buying an additional 56,506 shares during the period. Aperio Group LLC boosted its position in AbbVie by 5.2% in the third quarter. Aperio Group LLC now owns 752,585 shares of the company’s stock worth $47,466,000 after buying an additional 37,055 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in AbbVie by 4.0% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,701,437 shares of the company’s stock worth $296,520,000 after buying an additional 182,686 shares during the period. Finally, WASHINGTON TRUST Co boosted its position in AbbVie by 1.1% in the third quarter. WASHINGTON TRUST Co now owns 136,621 shares of the company’s stock worth $8,617,000 after buying an additional 1,543 shares during the period. 66.67% of the stock is currently owned by institutional investors.
Shares of AbbVie Inc. (NYSE:ABBV) opened at 60.51 on Tuesday. The stock has a market capitalization of $98.33 billion, a price-to-earnings ratio of 16.67 and a beta of 1.57. The firm’s 50 day moving average is $61.67 and its 200 day moving average is $62.49. AbbVie Inc. has a 52-week low of $51.60 and a 52-week high of $68.12.
AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 27th. The company reported $1.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.20. AbbVie had a return on equity of 141.55% and a net margin of 23.22%. The business earned $6.78 billion during the quarter, compared to analyst estimates of $6.92 billion. During the same quarter last year, the firm earned $1.13 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. Equities analysts expect that AbbVie Inc. will post $5.48 earnings per share for the current year.
“J.P. Marvel Investment Advisors LLC Lowers Stake in AbbVie Inc. (ABBV)” was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another site, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this piece can be accessed at http://sleekmoney.com/j-p-marvel-investment-advisors-llc-lowers-stake-in-abbvie-inc-abbv/1659570.html.
A number of research analysts have recently commented on ABBV shares. Vetr upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $67.75 price target on the stock in a report on Monday, November 21st. Leerink Swann started coverage on shares of AbbVie in a report on Tuesday, October 18th. They issued a “market perform” rating and a $70.00 price target on the stock. Jefferies Group LLC restated a “buy” rating and issued a $90.00 price target on shares of AbbVie in a report on Thursday, January 5th. Citigroup Inc. cut shares of AbbVie from a “buy” rating to a “neutral” rating and set a $60.00 price target on the stock. in a report on Monday, November 28th. Finally, Credit Suisse Group cut shares of AbbVie from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $70.00 to $60.00 in a report on Monday, October 31st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $70.17.
In other AbbVie news, CFO William J. Chase sold 6,600 shares of the firm’s stock in a transaction that occurred on Friday, December 2nd. The stock was sold at an average price of $59.19, for a total transaction of $390,654.00. Following the completion of the sale, the chief financial officer now owns 178,970 shares in the company, valued at approximately $10,593,234.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.11% of the stock is currently owned by company insiders.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/j-p-marvel-investment-advisors-llc-lowers-stake-in-abbvie-inc-abbv/1659570.html
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.